Product Defect

Migliaccio & Rathod LLP Appointed to Help Lead Valsartan Litigation

Posted on

Migliaccio & Rathod LLP File Nationwide Class Action Complaint Against Major Pharmaceutical Companies for Contaminated Valsartan Sales and Are Appointed by Court to Plaintiffs’ Steering Committee Migliaccio & Rathod, as an appointed member of the Plaintiffs’ Steering Committee and co-lead of the Medical Monitoring group, have filed a Consolidated Amended Class Action Complaint against Teva, […]

Product Defect

Valsartan Carcinogenic Contaminants Investigation

Posted on

Migliaccio & Rathod LLP has filed a class action lawsuit against certain manufacturers of Valsartan, an angiotensin II receptor blocker used to treat high blood pressure and heart failure. The Food and Drug Administration issued a recall of Valsartan because it contained significant levels of N-nitrosodimethylamine (NDMA)—a probable human carcinogen—the long-term exposure of which increases […]